Jim Simons Pharma Cyte Biotech, Inc. Transaction History
Renaissance Technologies LLC
- $56.7 Billion
- Q2 2024
A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Pharma Cyte Biotech, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 48,500 shares of PMCB stock, worth $91,180. This represents 0.0% of its overall portfolio holdings.
Number of Shares
48,500
Previous 43,800
10.73%
Holding current value
$91,180
Previous $104,000
8.65%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding PMCB
# of Institutions
31Shares Held
1.12MCall Options Held
0Put Options Held
0-
K2 Principal Fund, L.P. Toronto, A6328KShares$615,7050.33% of portfolio
-
Vanguard Group Inc Valley Forge, PA192KShares$361,6870.0% of portfolio
-
Geode Capital Management, LLC Boston, MA177KShares$332,0170.0% of portfolio
-
Ayrton Capital LLC Westport, CT92.1KShares$173,1237.31% of portfolio
-
Equitec Proprietary Markets, LLC82.7KShares$155,5260.18% of portfolio
About PharmaCyte Biotech, Inc.
- Ticker PMCB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,750,100
- Market Cap $39M
- Description
- PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...